ClinicalTrials.gg

Program

disitamab vedotin

Also written as “RC48-ADC”, “Disitamab Vedotin” and “Disitamab Vedotin Injection”.

In Pfizer's pipeline, HER2-directed antibody-drug conjugate. Its studies are mostly in Stomach Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3 companies.

Furthest: phase 3, since Apr 8, 201836 company-led studies, 28 open or runningAcquisition: Pfizer acquired Seagen, Dec 2023Next primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen3022 open or runningphase 3since Apr 8, 2018Aug 20, 2016Dec 2026phase 3 · NCT06221748
Pfizer55 open or runningphase 3since Jun 9, 2023Apr 19, 2021Dec 11, 2026phase 2 · NCT04879329
Jiangsu HengRui Medicine11 open or runningphase 2since Apr 26, 2024Apr 26, 2024Dec 31, 2031phase 2 · NCT06417554
  • Named in Pfizer’s own pipeline as disitamab vedotin PF-08046051, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Merck.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Aug 20, 2016.

  1. Jun 9, 2023Phase 3 study in Carcinoma, Transitional CellPfizer · NCT05911295 · 412 enrolled · United States, Argentina, Australia and more
  2. Jul 1, 2023Phase 3 study in Stomach NeoplasmsRemeGen · NCT05980481 · 201 enrolled · China
  3. Aug 15, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT06003231 · 120 enrolled · United States, Australia, Canada and more
  4. Aug 18, 2023Phase 2 study in Solid TumorRemeGen · NCT06016062 · 221 planned · China
  5. Nov 23, 20232 phase 2 studiesRemeGen · NCT06155396, NCT06155383
  6. Nov 27, 2023Phase 2 study in Breast NeoplasmsPfizer · NCT06157892 · 54 enrolled · United States, Australia, Canada and more
  7. Dec 3, 2023Phase 2 study in Breast NeoplasmsRemeGen · NCT06178159 · 40 planned · China
  8. Jan 15, 2024Phase 3 study in Stomach NeoplasmsRemeGen · NCT06221748 · 90 planned · China
  9. Jan 17, 20242 phase 2 studiesRemeGen · NCT06227156, NCT06227117
  10. Apr 12, 2024Phase 2 study in High-risk Non-muscle Invasive Bladder CancerRemeGen · NCT06378242 · 24 planned · China
  11. Apr 26, 2024Jiangsu HengRui Medicine's first study: phase 2 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06417554 · 80 planned · China
  12. Apr 17, 2025Phase 3 study in Stomach NeoplasmsRemeGen · NCT06944496 · 616 planned · China
  13. May 9, 2025Phase 2 study in Breast NeoplasmsPfizer · NCT06966453 · 74 enrolled · United States, Australia, Brazil and more
  14. Dec 3, 2025Phase 3 study in Stomach NeoplasmsRemeGen · NCT07315750 · 555 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsRemeGen · NCT06221748
  2. Dec 11, 2026Primary completion: phase 2 study in Carcinoma, Transitional CellPfizer · NCT04879329
  3. Dec 31, 2026Primary completion: phase 3 study in Carcinoma, Transitional CellRemeGen · NCT05302284
  4. Jan 29, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellPfizer · NCT05911295

TargetBeta

“HER2-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via the protease-cleavable linker maleimidocaproyl-valine-…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 36 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07315750Stomach Neoplasms · China3RecruitingRemeGenJun 30, 2029555
NCT06966453Breast Neoplasms · United States, Australia, Brazil and more2Active, not recruitingPfizerOct 25, 202774
NCT06944496Stomach Neoplasms · China3Not yet recruitingRemeGenMay 15, 2028616
NCT06417554Advanced Solid Tumors · China2RecruitingJiangsu HengRui MedicineDec 31, 203180
NCT06378242High-risk Non-muscle Invasive Bladder Cancer · China2RecruitingRemeGenMar 15, 202924
NCT06227156Castration-resistant Prostate Cancer · China2RecruitingRemeGenDec 202540
NCT06227117Breast Neoplasms · China2RecruitingRemeGenDec 2025120
NCT06221748Stomach Neoplasms · China3RecruitingRemeGenDec 202690
NCT06178159Breast Neoplasms · China2RecruitingRemeGenJun 202640
NCT06157892Breast Neoplasms · United States, Australia, Canada and more2Active, not recruitingPfizerJul 28, 202954
NCT06155396Uterine Cervical Neoplasms · China2RecruitingRemeGenJun 30, 2027116
NCT06155383Stomach Neoplasms · China2RecruitingRemeGenJan 31, 202590
NCT06016062Solid Tumor · China2RecruitingRemeGenDec 31, 2025221
NCT06003231Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Active, not recruitingPfizerMar 27, 2026120
NCT05980481Stomach Neoplasms · China3Active, not recruitingRemeGenJul 10, 2025201
NCT05911295Carcinoma, Transitional Cell · United States, Argentina, Australia and more3Active, not recruitingPfizerJan 29, 2027412
NCT05940896Solid Tumor · China1RecruitingRemeGenNov 16, 202424
NCT05943379Non-Muscle Invasive Bladder Neoplasms · China2RecruitingRemeGenDec 1, 202585
NCT05745740Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingRemeGenDec 1, 202726
NCT05302284Carcinoma, Transitional Cell · China3RecruitingRemeGenDec 31, 2026452
NCT05297552Muscle Invasive Bladder Carcinoma · China2RecruitingRemeGenJun 1, 202440
NCT05135715Melanoma · China2RecruitingRemeGenDec 30, 202450
NCT04965519Gynecological Malignancy · China2RecruitingRemeGenOct 2024120
NCT04879329Carcinoma, Transitional Cell · United States, Argentina, Australia and more2RecruitingPfizerDec 11, 2026372
NCT04714190Stomach Neoplasms · China3RecruitingRemeGenDec 1, 2024351
NCT04400695Breast Neoplasms · China3RecruitingRemeGenDec 31, 2027366
NCT04329429Biliary Tract Neoplasms · China2Active, not recruitingRemeGenNov 3, 202357
NCT04311034Carcinoma, Non-Small-Cell Lung · China2CompletedRemeGenDec 21, 202137
NCT04073602Carcinoma, Transitional Cell · China2CompletedRemeGenSep 30, 202219
NCT03809013Carcinoma, Transitional Cell · China2CompletedRemeGenMar 4, 202164
NCT03556345Stomach Neoplasms · China2CompletedRemeGenJun 1, 2020127
NCT03507166Carcinoma, Transitional Cell · China2CompletedRemeGenOct 29, 201843
NCT03500380Breast Neoplasms · China3Active, not recruitingRemeGenJul 31, 2024301
NCT03052634Advanced Breast Cancer · China2CompletedRemeGenJul 31, 2022112
NCT02881190Solid Tumors · China1CompletedRemeGenJun 27, 201957
NCT02881138Solid Tumors · China1CompletedRemeGenApr 30, 202024

How it is read

Names in the registry

  • “RC48-ADC”, 15 entries
  • “disitamab vedotin”, 4 entries
  • “Disitamab Vedotin”, 3 entries
  • “Disitamab Vedotin Injection”, 3 entries
  • “Disitamab vedotin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.